mTOR activates the VPS34-UVRAG complex to regulate autolysosomal tubulation and cell survival by Munson, Michael J. et al.
Article
mTOR activates the VPS34–UVRAG complex to
regulate autolysosomal tubulation and cell survival
Michael J Munson1, George FG Allen1, Rachel Toth1, David G Campbell1, John M Lucocq2 &
Ian G Ganley1,*
Abstract
Lysosomes are essential organelles that function to degrade and
recycle unwanted, damaged and toxic biological components. Lyso-
somes also act as signalling platforms in activating the nutrient-
sensing kinase mTOR. mTOR regulates cellular growth, but it
also helps to maintain lysosome identity by initiating lysosomal
tubulation through a process termed autophagosome-lysosome
reformation (ALR). Here we identify a lysosomal pool of phosphati-
dylinositol 3-phosphate that, when depleted by specific inhibition
of the class III phosphoinositide 3-kinase VPS34, results in
prolonged lysosomal tubulation. This tubulation requires mTOR
activity, and we identified two direct mTOR phosphorylation sites
on UVRAG (S550 and S571) that activate VPS34. Loss of these phos-
phorylation sites reduced VPS34 lipid kinase activity and resulted
in an increase in number and length of lysosomal tubules. In cells
in which phosphorylation at these UVRAG sites is disrupted, the
result of impaired lysosomal tubulation alongside ALR activation is
massive cell death. Our data imply that ALR is critical for cell
survival under nutrient stress and that VPS34 is an essential regu-
latory element in this process.
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Introduction
Intracellular membrane compartmentalisation, to form organelles, is
vital to enable distinct biological processes to occur in a controlled
manner. Cellular components, such as lipids and proteins, must be
trafficked to and from these organelles in order for these processes
to occur. A fundamental question in cell biology concerns how
specific compartment identity is retained in spite of perpetual trans-
port to and from each organelle. A prime example of this is the lyso-
some, a digestive organelle that is often considered the end point of
many intracellular transport pathways including endocytosis,
phagocytosis and autophagy (Appelqvist et al, 2013; Puertollano,
2014). In spite of all this incoming material, lysosomes still maintain
their identity and basic structure. One mechanism by which lyso-
somes achieve this is through a process termed autophagosome-
lysosome reformation (ALR), which was identified from studies
following long-term starvation and the nutrient-sensing kinase
mTOR (Yu et al, 2010). Starvation through loss of amino acids leads
to inactivation of mTOR and induction of autophagy (Noda &
Ohsumi, 1998). This in turn induces bulk transport of autophago-
somes and their contents to lysosomes, generating large autolyso-
somes. Degradation of their contents replenishes amino acids to
allow synthesis of essential proteins to aid in survival. At a critical
point, the production of amino acids from degraded protein is suffi-
cient to re-activate mTOR, an important regulator of ALR that drives
reformation of lysosomes from autolysosomes via membrane tubu-
lation (Chen & Yu, 2013).
Multiple pathways that traffic material to the lysosomes require
the lipid kinase VPS34, the only known class III phosphoinositide
3-kinase (Backer, 2008; Raiborg et al, 2013). VPS34 catalyses the
phosphorylation of phosphatidylinositol (PI) at the three position
of the inositol ring to produce phosphatidylinositol 3-phosphate
(PI(3)P). PI(3)P then acts as a signalling molecule to recruit down-
stream proteins, such as those involved in membrane tethering and
fusion, mainly through PI(3)P-specific binding domains such as the
PX or FYVE domains (Di Paolo & De Camilli, 2006; Lemmon, 2008).
VPS34 regulation of multiple pathways is enabled by binding to
distinct protein complexes, which allow further spatiotemporal
regulation of the different trafficking pathways. In mammalian cells,
there are at least two distinct VPS34 complexes that each contain
VPS34, VPS15 and BECLIN1 and either ATG14L/BARKOR or
UVRAG (Kihara et al, 2001; Itakura et al, 2008; Sun et al, 2008).
The ATG14L-containing complex is primarily thought to function in
the autophagic pathway, while the UVRAG-containing complex
functions in the endocytic pathway (Simonsen & Tooze, 2009;
Funderburk et al, 2010).
By nature of its involvement in lysosomal trafficking pathways,
VPS34 has an indirect role on lysosomal function; however, we
were curious to examine whether VPS34 and its product PI(3)P play
a more direct role in regulating lysosomal function, thus providing a
1 MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee, UK
2 School of Medicine, University of St Andrews, St Andrews, UK
*Corresponding author. Tel: +44 1382 388905; E-mail: i.ganley@dundee.ac.uk
ª 2015 The Authors. Published under the terms of the CC BY 4.0 license The EMBO Journal 1
Published online: July 2, 2015 
mechanism for coordination of not only these distinct trafficking
pathways, but also their common end point.
Here, we uncover a role for VPS34 and PI(3)P at the lysosome
and identify mTOR phosphorylation sites on the VPS34 binding part-
ner UVRAG. Loss of these sites reduces VPS34 activity, leading to
persistent lysosomal tubulation and a failure to regenerate normal
lysosomes that results in increased cell death following starvation.
Results
To determine the role of VPS34 in lysosomal function, we titrated
the highly specific VPS34 inhibitor, VPS34-IN1 (Bago et al, 2014), to
generate a range of PI(3)P levels within the cell (Fig 1A). In order to
visualise intracellular PI(3)P, we stained fixed and permeabilised
cells with fluorescently tagged recombinant PX domain derived from
p40phox (Ellson et al, 2001). This protein domain is specific for
PI(3)P, and we prefer this method of staining as it avoids artefacts
and dominant-negative effects that can occur by overexpressing
high-affinity PI(3)P-binding domains in live cells. Using this
method, we found that 5 lM VPS34-IN1 reduced the PX domain
staining by 90%, while 1 lM reduced it by 60%. This is in good
agreement with our previous study showing that the inhibitor
blocked membrane association of intracellularly expressed tandem
FYVE domains (Bago et al, 2014). PI(3)P is known to function in
endocytic pathway sorting and in autophagy initiation, both of
which indirectly impinge upon lysosomal function. However, there
is little evidence to suggest that VPS34 and its product PI(3)P also
act directly at the lysosome itself. To examine whether PI(3)P is
present on lysosomes, we co-stained cells with the recombinant PX
domain and lysosomal associated membrane protein 1 (LAMP1)
and lysosomal adaptor and mTOR regulator (LAMTOR), both
endogenous lysosomal markers (Fig 1B). We identified a small but
significant pool of PX domain staining localised to both LAMP1 and
LAMTOR structures in cells (Fig 1C), indicating that PI(3)P is indeed
present on lysosomes. We further analysed another marker, CD63
(also known as LAMP3), which is enriched on lysosomes and again
found significant co-localisation with the PX domain (Supplemen-
tary Fig S1). Consistent with previous publications, we observed a
large proportion of the PX domain to label early endosomes (Ellson
et al, 2001; Supplementary Fig S1). We are currently unable to tell
whether it is a subset of lysosomes that contain PI(3)P or, more
likely given the evidence presented later, whether it is more a
temporal localisation with lysosomes acquiring PI(3)P at certain
stages in their lifetime. We found that treatment of cells with 1 lM
VPS34-IN1 dramatically reduced PX-LAMP1 colocalisation by 80%,
which, given the 60% reduction of total PX domain staining
(Fig 1A), suggests that this lysosomal pool of PI(3)P is particularly
sensitive to VPS34 inhibition. Additional evidence for a lysosomal
pool of PI(3)P was provided by transition electron microscopy. We
labelled cell sections with recombinant GST-tagged PX domain
followed by secondary anti-GST conjugated to gold particles and
found a small number of labelled structures that resemble
lysosomes in that they were multilamellar and often contained
pleiotropic membranous structures in their lumen (Fig 1D). We
were unable to perform double-labelling experiments, but found
that LAMP1 also labelled similar membranous profiles, further
supporting the idea that they are lysosomal (Fig 1E). Taken
together, the microscopy data strongly suggest PI(3)P is present on
lysosomes.
Given the dynamic nature of lysosomes and to preserve tubular
elements that can be disrupted by fixation (Sridhar et al, 2013), we
analysed lysosomal structures in live U2OS cells stably expressing
low levels of LAMP1-mCherry (Fig 2). Inhibition of VPS34 had a
clear effect on lysosomal morphology, both at 1 and at 5 lM VPS34-
IN1 (Fig 2A) with lysosomes appearing larger in general. Larger
lysosomes are seen upon PIKfyve inhibition, the lipid kinase that
uses PI(3)P to generate PI(3,5)P2, a phospholipid involved in regu-
lating endosomal and lysosomal size (Jefferies et al, 2008). It is
therefore possible that this larger lysosomal size is due to reduced
PI(3,5)P2 levels upon VPS34-IN1 treatment. Remarkably at 1 lM
VPS34-IN1, which inhibits lysosomal PI(3)P levels, a large increase
in lysosomal tubulation occurred (Fig 2A, right panels, and B).
These tubules are reminiscent of ALR where lysosomes regenerate
following starvation and reactivation of mTOR signalling (Yu et al,
2010). To determine whether the VPS34-IN1-induced tubules occur
through a related process, cells were treated in combination with
the specific mTOR inhibitor KU0063794 (shortened to KU here;
Garcı´a-Martı´nez et al, 2009; Fig 2A, left panels, and B). mTOR inhi-
bition is known to increase lysosomal size, and this had no effect on
the large lysosomes seen upon VPS34-IN1 treatment. However,
mTOR inhibition completely abolished the tubules formed upon
1 lM VPS34-IN1 treatment, implying these tubules are linked to
ALR. We also used GFP-LAMTOR as an additional lysosomal marker
and found this behaved in a very similar fashion to LAMP1-mCherry
with respect to tubule formation (Supplementary Fig S2).
As ALR initiates from autolysosomes, we further analysed the
nature of the LAMP1 tubules by stably expressing mCherry-LC3 in
our LAMP1-GFP cells (Fig 2C). Given its relative lysosomal stability,
mCherry derived from mCherry-LC3 will accumulate over time in
autolysosomes due to basal autophagy (Klionsky et al, 2012). We
therefore analysed tubule formation in these cells upon VPS34-IN1
treatment and found that over 90% of the LAMP1-GFP tubules also
contained the mCherry signal (Fig 2C and D). This demonstrates
that the tubules are forming from autolysosomes.
The dynamics of lysosome tubulation is shown in more detail in
Fig 2E, and the reader is encouraged to observe the movies that
these images are derived from (Supplementary Movie S1A and B).
Under control conditions, a small tubule can be seen to form on the
indicated LAMP1 structure (arrowhead, upper panels in Fig 2E), and
following approximately 30 s, the tubule buds off and becomes an
independent structure (arrow, upper panels in Fig 2E). In contrast,
treatment with VPS34-IN1 results in the formation of a tubule that
grows and extends towards another LAMP1 compartment (arrow,
lower panels in Fig 2E). The tubule persists and “springs” back after
around 300 s, implying that scission of the tubule is disrupted.
Given that VPS34 inhibition with VPS34-IN1 prolonged auto-
lysosomal tubulation, which in turn was blocked by mTOR
inhibition, we explored the possibility that mTOR may directly
control VPS34 activity. To analyse this further, we looked at the
VPS34 lipid kinase complex in more detail.
mTOR phosphorylates the UVRAG–VPS34 lipid kinase complex
To investigate the possibility that mTOR regulates VPS34, we exam-
ined lysates from three different cell lines (HeLa, U2OS and MEF)
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Figure 1. PI(3)P is present at the lysosome.
A U2OS cells were treated with indicated concentrations of VPS34-IN1 for 1 h, fixed and stained with a recombinant PX domain Alexa Fluor-594 conjugate. Graph
represents mean PX domain staining following titration of VPS34-IN1 in U2OS cells for 1 h  SEM for n = 3 independent experiments. Scale bar, 10 lm.
B U2OS cells were treated for 1 h as indicated and stained for LAMP1 or LAMTOR and PI(3)P utilising the PX domain conjugate; arrowheads indicate co-localising
punctate structures. Scale bar, 10 lm.
C Quantitation of LAMP1 or LAMTOR and PX domain co-localisation from (B), mean  SEM for n = 3 independent experiments. Significance was determined by
Student’s t-test, *P < 0.05.
D Transition electron micrograph sections of U2OS cells grown in complete medium and labelled with recombinant GST-PX domain and anti-GST gold conjugate. Scale
bar, 500 nm.
E Electron micrograph sections of U2OS cells as in (D) labelled for PX domain or LAMP1. Scale bar, 500 nm.
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Figure 2. Inhibition of VPS34 alters autolysosomal morphology.
A Images from live U2OS cells stably expressing LAMP1-mCherry that were treated as indicated for 1 h. White squares denote magnified regions shown to the right.
Scale bar, 10 lm.
B Quantitation from (A) of mean tubules per cell and tubule length as indicated  SEM for n = 3 independent experiments.
C Live cell images of U2OS cells expressing LAMP1-GFP and mCherry-LC3 grown in complete medium and treated with DMSO or 1 lM VPS34-IN1 for 1 h. Arrow heads
in boxed regions highlight tubular co-localisation of LAMP1-GFP and mCherry-LC3.
D Quantitation of co-localisation of LAMP1 tubules with LC3 from (C). Mean  SEM for n = 3 independent experiments.
E Still images from live cell microscopy shown in Supplementary Movie S1A and B. For control (DMSO), magnified frames are shown above the cell from the area
marked with an asterisk. For VPS34-IN1 treatment, frames are shown below. Arrowheads indicate initiation site of LAMP1 tubules, while arrows indicate the leading
edge of tubules. Scale bar, 10 lm.
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grown under control conditions, treated with the mTOR inhibitor KU
or incubated in amino acid-free Earle’s balanced salt solution (EBSS),
which also results in mTOR inhibition (Fig 3A). Immunoblot
analysis confirmed mTOR inhibition by KU and EBSS, as indicated
by a loss of ULK1 phosphorylation at the mTOR site (serine 757) and





Figure 3. mTORC1 phosphorylates the UVRAG–VPS34 lipid kinase complex.
A HeLa, U2OS and MEFs were treated in complete medium (control), 1 lM KU0063794 (KU) or EBSS for 1 h (MEFs) or 2 h (HeLa, U2OS) prior to lysis and immunoblot.
B Cell lysate fromMEFs grown in complete medium was treated in the presence or absence of lambda phosphatase with or without phosphatase inhibitors for 30 min at 30°C.
C RICTOR +/+ and / MEFs were grown in complete medium (control), 1 lM KU or EBSS for 1 h prior to lysis.
D Endogenous RAPTOR (RPTOR) or IgG control was immunoprecipitated from HEK293 cells and utilised for an in vitro kinase assay (Materials and Methods) with
substrates GST-p70S6K D236A, GST-UVRAG, GST-ATG14L or FLAG-BECLIN1 in the presence or absence of KU.
E Quantitation of relative phosphorylation of GST-p70S6K and GST-UVRAG in the presence or absence of KU from (D). Data represents mean  SEM for
n = 3 independent experiments. Significance was determined by Student’s t-test, ***P < 0.001.
Source data are available online for this figure.
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of another known mTOR substrate, 4E-BP1. As VPS34 exists in two
core complexes containing either UVRAG or ATG14L, we analysed
these along with VPS34 and BECLIN1. No notable change was
observed in any VPS34 component except for the protein UVRAG,
which ran as a doublet under normal conditions, but exhibited loss
of the upper band upon mTOR inhibition. As an electrophoretic
mobility shift can be indicative of phosphorylation, we confirmed
this by treating MEF lysates grown under normal conditions with k
phosphatase that has broad non-specific phosphatase activity (Zhuo
et al, 1993) (Fig 3B). k Phosphatase caused a mobility shift but this
was prevented in the presence of phosphatase inhibitors, confirming
that UVRAG is indeed phosphorylated under conditions where
mTOR is active.
mTOR is present in two distinct complexes, mTORC1 and
mTORC2, both of which can be inhibited by the KU compound
(Garcı´a-Martı´nez et al, 2009). To determine mTORC2 involve-
ment, we examined UVRAG mobility in SDS–PAGE gels with
lysates from mTORC2-deficient, RICTOR-null MEFs. UVRAG demon-
strated a comparable mobility shift in both RICTOR-positive and
RICTOR-negative cells, indicating mTORC2 is not required (Fig 3C).
In contrast to KU, the specific mTORC1 inhibitor rapamycin only
partially blocked the mobility shift of UVRAG, as it did for 4E-BP1
also, indicating that residual UVRAG phosphorylation may be due
to the rapamycin-insensitive properties of mTORC1 (Choo et al,
2008; Kang et al, 2013).
To confirm that mTOR can phosphorylate UVRAG, we carried out
in vitro kinase assays using RAPTOR immunoprecipitation (IP) as a
source of endogenous mTORC1 complex. For substrates, we used
recombinant GST-UVRAG as well as the VPS34 binders GST-ATG14L
and FLAG-BECLIN1. We also included GST-p70S6K D236A (kinase
dead), a known mTORC1 substrate as a positive control (Fig 3D).
Autoradiography to detect 32P incorporation into substrates revealed
that UVRAG is highly phosphorylated by mTORC1 at a level that was
greater than the known substrate p70S6K. We observed no phos-
phorylation by mTORC1 on BECLIN1 and a small degree of ATG14L
phosphorylation, which is in support of the recent observation that
mTOR can regulate ATG14L (Yuan et al, 2013). Interestingly, we did
observe a phosphorylated band at the position of BECLIN1 in the
UVRAG samples, which could imply that mTOR can phosphorylate
BECLIN1 when it is part of the UVRAG complex. Further work will
be needed to clarify this. Phosphorylation of each substrate was
sensitive to KU treatment, indicating that mTOR is the major phos-
phorylating kinase. Indeed, UVRAG sensitivity to KU was equivalent
to p70S6K, further implicating UVRAG as a direct mTOR substrate
(Fig 3E). Given the mTOR-dependent electrophoretic mobility shift
of UVRAG derived from cells and in vitro phosphorylation by mTOR,
we examined this event in further detail.
mTOR phosphorylates UVRAG at serine 550 and serine 571
To identify the phosphorylation sites on UVRAG, two approaches
were undertaken. GST-UVRAG was incubated in vitro with
endogenous mTOR and phosphorylated in a non-radioactive kinase
assay in the absence or presence of KU. Alternatively, MEFs stably
expressing FLAG-UVRAG were treated with/without KU and
UVRAG immunoprecipitated using FLAG agarose. In each experi-
ment, samples were separated by SDS–PAGE and the Coomassie-
stained UVRAG band was excised for phospho-peptide analysis by
mass spectrometry. The in vitro kinase assay identified two phos-
phorylated sites that were abolished upon KU treatment, serine 550
(S550) and serine 571 (S571, Fig 4A). Analysis of UVRAG immuno-
precipitated from cells also identified S550 and S571 as being phos-
phorylated in cells and sensitive to KU treatment. From the
immunoprecipitated UVRAG only, we also identified two additional
sites that were phosphorylated at serine 498 and threonine 518.
However, unlike S550 and S571, these sites were insensitive to KU
treatment and a UVRAG mutant with these residues substituted to
alanine was still phosphorylated in vitro by mTOR, implying that
another kinase mediates phosphorylation at these sites (Supplemen-
tary Fig S3). Combined, the in vitro and cell data clearly indicate
that mTORC1 phosphorylates UVRAG at two distinct sites. The
domain structure of UVRAG is represented in Fig 4B with an
alignment of human UVRAG residues 540–582, the region where
phosphorylated serines were identified. Both S550 and S571
residues are positioned with a +1 leucine that is favourable for
mTOR-mediated phosphorylation (Hsu et al, 2011) and are well
conserved across higher eukaryotes, further supporting that these
are mTOR sites.
To provide more evidence of S550 and S571 phosphorylation, the
serine residues were mutated to alanines that cannot be phosphory-
lated as they lack a hydroxyl group. The GST-UVRAG alanine
mutants were incubated in vitro with endogenous mTORC1 that was
immunoprecipitated via RAPTOR (Fig 4C and D). Mutation of S550
to alanine (S550A) reduced phosphorylation in vitro. A reduction
was also observed when S571 was mutated to alanine (S571A) and
UVRAG with combined S550A and S571A mutations (dblA) resulted
in an additive loss of 32P incorporation. UVRAG dblA reduced
mTOR-mediated phosphorylation by ~70%, similar to that of wild-
type (WT) UVRAG phosphorylation in the presence of KU (Fig 4D).
This implies that S550 and S571 are the primary mTORC1-mediated
phosphorylation sites. The residual KU-insensitive 32P incorporation
into UVRAG likely results from a contaminating kinase associated
with the mTOR IP.
To confirm that UVRAG is phosphorylated at S550 and S571 in
cells, we generated phospho-specific antibodies to these sites. IP of
stably expressed GFP-UVRAG from cells under control conditions
produced immunoreactivity with both the phospho-specific S550
and the phospho-specific S571 antibodies. Importantly, this signal
was lost when cells were incubated with EBSS to inhibit mTOR
activity (Fig 4E). As a control, cells expressing GFP-UVRAG dblA at
a similar level to WT GFP-UVRAG failed to produce any reactivity
with the phospho-specific antibodies under any condition. Impor-
tantly, WT GFP-UVRAG displayed the same electrophoretic mobility
shift as endogenous UVRAG upon mTOR inhibition while the dblA
mutant did not, indicating that the UVRAG band shift represents
dephosphorylation at the S550 and S571 residues.
We were also able to detect S550 phosphorylation on endoge-
nous UVRAG in cell lysates (Fig 4F). Satisfyingly, the phospho-S550
kinetics closely matched the UVRAG band shift as well as that of the
known mTOR substrates 4E-BP1 and p70S6K, showing that UVRAG
behaves as a conventional mTOR substrate.
UVRAG phosphorylation enhances VPS34 lipid kinase activity
UVRAG has been shown to enhance VPS34 activity (Liang et al,
2006; Sun et al, 2010). Given that our original observation showed
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Figure 4. mTOR phosphorylates UVRAG at serine 550 and serine 571.
A Extracted ion chromatogram of peptide K543–K559 (S550) and K564–R595 (S571) following in vitro kinase assay of GST-UVRAG with IgG control or endogenous mTOR
in the presence or absence of 1 lM KU0063794 (KU).
B Domain structure of UVRAG containing an N-terminal proline-rich region (PRR), C2 domain and a coiled-coil domain (CCD). Sequence alignment of human UVRAG
540–582 indicates S550 and S571 (highlighted) which are conserved between species within the C-terminal domain.
C In vitro kinase assay of endogenous mTORC1 by RAPTOR immunoprecipitation from HEK293 cells with GST-UVRAG wild-type (WT), S550A, S571A or S550A+S571A
double (dblA) mutants.
D Quantitation of (C), bars represent mean 32P incorporation  SEM of n = 4 independent experiments. Statistical analysis was carried out by one-way ANOVA and
Dunnett’s multiple comparison test to the WT control, *P < 0.05 and ***P < 0.001.
E U2OS cells stably expressing WT or dblA GFP-UVRAG were incubated in complete medium (ctrl) or EBSS for 2 h prior to immunoprecipitation with anti-GFP sepharose
and immunoblotting with phospho-specific antibodies.
F Wild-type MEFS were washed twice and incubated in EBSS for 1 h prior to refeed with complete medium for 45 min and lysed at time points indicated.
Source data are available online for this figure.
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that VPS34 activity was important in mTOR-dependent lysosomal
tubulation (Fig 2), we examined whether mTOR phosphorylation of
UVRAG altered VPS34 activity. We first analysed endogenous
UVRAG-associated VPS34 activity in an in vitro lipid kinase assay to
measure PI(3)P production (Fig 5A). Endogenous UVRAG was
immunoprecipitated from cells under control conditions or those
with mTOR inhibition and loss of UVRAG phosphorylation (either
directly by KU treatment or indirectly through EBSS incubation). A
significant drop in VPS34 activity of 50% was observed in U2OS cells
upon mTOR inhibition, with KU treatment and EBSS incubation
having a similar effect on activity. To see whether this reduction in
VPS34 activity was due to loss of UVRAG–mTOR phosphorylation,
we carried out similar experiments in cells stably expressing WT or
dblA FLAG-UVRAG (Fig 5B). Exogenous UVRAG was immunopreci-
pitated from cells, treated as in Fig 5A, using the FLAG tag. WT
FLAG-UVRAG behaved very similar to endogenous UVRAG in that
the associated VPS34 activity was reduced by 60% upon mTOR inhi-
bition with EBSS. The dblA mutant also displayed similar VPS34
activity upon EBSS treatment; however, critically, this activity did
not increase under control conditions where mTOR is active. This
suggests that S550 and S571 are essential to mediate the increased
VPS34 activity under control conditions with complete medium.
To support the in vitro VPS34 activity data, we used the PX
domain staining method to visualise PI(3)P in cells (Fig 5C–E). To
look at PI(3)P levels associated with UVRAG phosphorylation,
we treated cells with KU and EBSS to inhibit mTOR. As with the
in vitro VPS34 assays, inhibition of mTOR in cells resulted in a 50%
loss of PX domain staining, indicating a reduction in cellular VPS34
activity (Fig 5C, top panels, and E). To confirm that the reduction in
PI(3)P staining was due to loss of UVRAG phosphorylation, we used
siRNA to deplete endogenous UVRAG in cells stably expressing
similar levels of either WT or dblA siRNA-resistant GFP-UVRAG
(Fig 5D). Loss of UVRAG alone caused a reduction in PX domain
staining, supporting previous observations that UVRAG is important
for VPS34 activity (Liang et al, 2006; Sun et al, 2010). This loss was
similar to control-depleted cells treated with KU or EBSS and was
not further reduced upon mTOR inhibition (Fig 5C and E). Rescue
of the UVRAG siRNA with expression of resistant WT UVRAG
restored PX domain staining levels to that seen in control cells,
ruling out UVRAG siRNA off-target effects. By contrast, expression
of a similar level of dblA UVRAG failed to restore PX domain
staining seen in control cells and displayed similar levels to the
UVRAG-only depleted cells. Taken together with the in vitro data,
this suggests that mTOR-mediated UVRAG phosphorylation at S550
and S571 enhances VPS34 activity. Consistent with the data
presented here, mTOR inhibition has previously been shown to
inhibit total levels of cellular PI(3)P (Byfield et al, 2005; Russell
et al, 2013; Yuan et al, 2013); our data now demonstrate this inhibi-
tion is due to UVRAG dephosphorylation. It is important to note that
mTOR inhibition does not reduce all pools of PI(3)P. The auto-
phagy-initiating VPS34 complex, which contains ATG14L instead of
UVRAG, is enhanced under these conditions, though the increase in
autophagic PI(3)P is small compared to the total pool.
Given that the molecular make-up of the different VPS34
complexes is important for lipid kinase activity, it was important to
check whether the VPS34-associated proteins changed upon UVRAG
phosphorylation. We immunoprecipitated endogenous UVRAG from
cells under control conditions or those of mTOR inhibition with KU
or EBSS (Fig 5F) and found that a similar amount of VPS34 and
BECLIN1 co-immunoprecipitated regardless of the condition,
suggesting phosphorylation does not alter UVRAG binding to the
core VPS34 complex. Next, we immunoprecipitated endogenous
VPS34 under similar conditions (Fig 5G) and found that mTOR inhi-
bition did not alter the amount of associating UVRAG, BECLIN1,
ATG14L or RUBICON, suggesting UVRAG phosphorylation does not
alter VPS34 complex stoichiometry. Finally, we immunoprecipitated
stably expressed GFP-UVRAG from cells and found a similar amount
of VPS34, BECLIN1 and RUBICON co-immunoprecipitating with
either WT or the phosphorylation-deficient dblA mutant (Fig 5H).
Therefore, our data suggest the reduction in VPS34 activity upon
loss of UVRAG dephosphorylation is not due to disruption of estab-
lished VPS34 binding partners.
UVRAG phosphorylation alters lysosomal morphology
To determine whether UVRAG phosphorylation had any major
effects on multiple membrane compartments, we utilised siRNA and
our GFP-UVRAG rescue cells to look at cis-Golgi (GM130 staining),
early endosomes (early endosomal antigen 1—EEA1) and late endo-
somes (cation-independent mannose-6 phosphate receptor—CI-
MPR) (Supplementary Fig S4A). In fixed cells, depletion of UVRAG
resulted in a dispersed and fragmented staining pattern of GM130.
This is consistent with an earlier publication implicating UVRAG in
Golgi-ER transport, disruption of which causes Golgi fragmentation
▸Figure 5. UVRAG phosphorylation enhances VPS34 lipid kinase activity.A U2OS cells were incubated in complete medium (ctrl), 1 lM KU0063794 (KU) or EBSS for 2 h. Endogenous UVRAG was immunoprecipitated and associated VPS34
kinase activity determined by in vitro kinase assay (see Material and Methods). Graph represents mean VPS34 activity (following normalisation to VPS34 protein
level)  SEM for n = 3 independent experiments; significance was determined by one-way ANOVA and Dunnett’s multiple comparison test to the control,
*P < 0.05.
B U2OS cells stably expressing wild-type (WT) or S550A+S571A (dblA) FLAG-UVRAG were incubated in complete medium (ctrl) or EBSS for 2 h prior to IP with FLAG
agarose and in vitro kinase assay of associated VPS34 activity. Graph represents mean VPS34 activity  SEM for n = 4 independent experiments; significance was
determined by two-way ANOVA and Bonferroni post-tests, ***P < 0.001.
C Control MEFs or those stably expressing WT or dblA GFP-UVRAG were transfected with 100 nM UVRAG siRNA 40 h prior to treatment. Cells were treated as ctrl, KU
or EBSS for 1 h prior to fixation and staining for PI(3)P with PX domain conjugate. Scale bar, 10 lm.
D Example blot of UVRAG siRNA knockdown and rescue as in (C).
E Quantitation of (C) where bars represent mean PX domain staining  SEM for n = 4 independent experiments, significance was determined by two-way ANOVA
and Bonferroni post-tests, *P < 0.05.
F, G IP of endogenous (F) UVRAG or (G) VPS34 from U2OS cells following ctrl, KU or EBSS treatment for 2 h.
H HeLa cells stably expressing WT or dblA GFP-UVRAG were incubated in complete medium prior to IP with GFP sepharose beads.
Source data are available online for this figure.
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(He et al, 2013). However, expression of siRNA-resistant WT or
dblA GFP-UVRAG rescued this phenotype suggesting UVRAG phos-
phorylation does not affect Golgi integrity. Little change in EEA1 or
CI-MPR staining was observed upon depletion of UVRAG or rescue
with the dblA mutant, implying UVRAG phosphorylation does not
play an important role in maintenance of these compartments,
although we cannot rule out subtle changes at this resolution.
UVRAG depletion, however, had a clear effect on LAMP1 staining
(Fig 6A–C). Loss of UVRAG resulted in a small decrease in LAMP1
puncta that were larger in size, similar to the effect seen with high
doses of VPS34-IN1 treatment (see Fig 2A), a phenotype that was
rescued by expression of WT GFP-UVRAG. In contrast, rescue of the
UVRAG depletion with dblA GFP-UVRAG expression resulted in a
large increase in smaller dispersed LAMP1 structures (Fig 6A and
C). To confirm that reduction of VPS34 activity upon loss of the
mTOR-UVRAG phosphorylation sites altered lysosomal PI(3)P
levels, we carried out LAMP1-PX domain staining in the GFP-
UVRAG rescue cells (Fig 6D and E). In very good agreement with
the inhibitor data shown in Fig 1B and C, we found that loss of
UVRAG resulted in a decrease in LAMP1-PX colocalisation, which
was rescued by expression of WT GFP-UVRAG, but not the dblA
mutant. We do not think that that the reduction in PX domain stain-
ing is due to mislocalisation of the dblA GFP-UVRAG mutant. Both
WT and dblA GFP-UVRAG show a similar localisation with a large
proportion co-localising with LAMP1-mCherry (Supplementary
Fig S4B). This therefore provides additional support for the VPS34–
UVRAG complex in regulating lysosomal function.
Given that LAMP1 tubules can be disrupted and fragmented by
fixation, potentially giving rise to smaller structures (Sridhar et al,
2013), we next analysed the effect of UVRAG phosphorylation on
lysosomal morphology in live cells. To monitor lysosome tubula-
tion, we stably expressed LAMP1-mCherry in our GFP-UVRAG
siRNA-rescue cell lines (Fig 7A—the reader is also encouraged to
look at the accompanying example movies (Supplementary Movie
S2A–C), which particularly highlight the morphology). Depletion of
endogenous UVRAG in cells expressing WT GFP-UVRAG showed a
lysosomal morphology very similar to control cells, with a small
number of tubules per cell and the majority being < 1 lm in length.
However, expression of the dblA GFP-UVRAG mutant resulted in an
approximate threefold increase in the total number of tubules
(Fig 7B). The majority of these were now twice as long as those
observed in WT-expressing cells, with some extending over 10 lm
in length, similar to the long tubules observed upon direct VPS34
inhibition with lower concentrations of VPS34-IN1 (compare with
Fig 2A and B). Interestingly, the levels of PI(3)P staining in cells
expressing the dblA UVRAG mutant and in cells treated with the
tubule-inducing concentration of VPS34-IN1 are approximately
equal, with a twofold reduction in levels (compare Fig 1A with 5C
and E). Therefore, inhibition of VPS34 activity directly with VPS34-
IN1 or by mutation of the mTOR phosphorylation sites results in
lysosomal tubulation. We do note that mTOR inhibition blocks
tubule formation, in apparent contradiction of the dblA UVRAG
phospho-mutant. However, as is discussed later, this can be
explained whether mTOR acts at multiple steps in tubule formation,
including before the mTOR-UVRAG-VPS34 requirement.
One characteristic of lysosomal tubules formed during ALR is
that they lack lysotracker staining or that of resident hydrolases
(Sridhar et al, 2013). To analyse the tubules formed in the dblA
GFP-UVRAG-expressing cells, we co-stained the LAMP1-mCherry
cells with lysotracker. As can be seen in Fig 7C, LAMP1 structures
stained with lysotracker with approximately equal intensity in either
WT or dblA UVRAG-expressing cells, suggesting global lysosomal
acidification was not impaired by loss of mTOR-mediated UVRAG
phosphorylation. Importantly, the tubules formed in the dblA-
expressing cells were still lysotracker positive. This could suggest
that these tubules are different in nature to the ALR tubules or that
inhibition of the mTOR-activated VPS34 impairs the selectivity
mechanism, for example by simply allowing the tubules to persist
attached to the originating lysosome. Data presented here showing
such persistent tubules certainly support the latter conclusion.
A main question arising is what are the consequences of impaired
tubule regulation for lysosomal function? VPS34 inhibition itself is
well characterised in disrupting lysosomal function, primarily
through blocking sorting and trafficking of receptors and hydrolases
on route to lysosomes (Raiborg et al, 2013). However, the UVRAG
phospho-mutants allow us to look more specifically at VPS34 func-
tion involved in lysosomal tubulation. A commonly used method to
investigate lysosomal trafficking and degradation is monitoring
epidermal growth factor receptor (EGFR) turnover. Upon stimulation
with EGF, EGFR at the cell surface becomes activated, internalised
and trafficked to the lysosome where the receptor is degraded. The
majority of the tubulation experiments detailed so far were carried
out in U2OS cells, and unfortunately, for this assay, we found that
these cells express a relatively low level of EGFR. To overcome this
assay, we switched to HeLa cells that express a much higher EGFR
level (Supplementary Fig S5A). Depletion of endogenous UVRAG in
cells expressing siRNA-resistant GFP-UVRAG (either WT or dblA)
did not cause any noticeable change in the degradation of EGFR
upon EGF stimulation (Fig 7D), implying mTOR-mediated UVRAG
phosphorylation does not disrupt trafficking to the lysosome or its
degradative capacity. This is supported by the fact that lysosomes
are still acidified in UVRAG phospho-mutant cells (Fig 7C). The lack
of disruption to lysosomal trafficking is supported by the observation
that mTOR inhibition with KU also fails to significantly change the
EGFR degradation rate (Supplementary Fig S5B and C). Similarly, it
does not alter another membrane trafficking route, that of transferrin
receptor recycling (Supplementary Fig S5D–F). These data suggest
that mTOR activity does not play a major role in regulation of
trafficking to the lysosome or general endocytic function.
A lysosomal trafficking pathway that is altered by mTOR inhibi-
tion is that of macroautophagy, being strongly induced at least in
part by removal of inhibitory mTOR phosphorylation sites on the
autophagy-activating ULK1 complex (Ganley et al, 2009; Hosokawa
et al, 2009; Jung et al, 2009). The role of UVRAG in autophagy is
debatable, with studies showing both a positive role (Liang et al,
2006) and no role (Itakura et al, 2008; Knævelsrud et al, 2010; Jiang
et al, 2014). Given the nature of the UVRAG-mTOR-mediated phos-
phorylation, it would be expected not to play a role in autophagy
induction, though it is possible that it may play a role in fusion and
clearance of mature autophagosomes. To analyse this, we used the
classical LC3 flux assay to look at the increase in LC3-II upon lyso-
somal inhibition (with bafilomycin A1) under normal conditions or
autophagy inducing mTOR inhibition (with EBSS). We found that
loss of UVRAG in the siRNA-resistant GFP-UVRAG-expressing cells,
either WT or dblA, had no significant effect on LC3 flux under
control conditions or short-term autophagy induction with EBSS
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Figure 6. UVRAG phosphorylation alters lysosomal morphology.
A U2OS cells or those stably expressing wild-type (WT) or S550A+S571A (dblA) GFP-UVRAG were transfected with 100 nM control or UVRAG siRNA 40 h prior to
treatment. Cells were grown in complete medium prior to fixation and staining for LAMP1. Scale bar, 10 lm.
B Western blot of endogenous UVRAG depletion and rescue with GFP-UVRAG as described in (A).
C Quantitation of LAMP1 punctate structures and size from (A), mean  SEM for n = 3 independent experiments, significance was determined by one-way ANOVA and
Dunnett’s multiple comparison test to the siCTRL, ***P < 0.001 and n.s = not significant.
D U2OS cells or those stably expressing wild-type (WT) or S550A+S571A (dblA) GFP-UVRAG were transfected with 100 nM control or UVRAG siRNA 40 h prior to
treatment. Cells were grown in complete medium prior to fixation and staining for LAMP1 and PX domain. Scale bar, 10 lm. Arrowheads indicate co-localising
punctate structures.
E Quantitation of LAMP1 co-localisation with PX domain as in (D)  SEM from n = 3 independent experiments. Significance was determined by one-way ANOVA and
Dunnett’s multiple comparison test to the siCTRL, **P < 0.01.
Source data are available online for this figure.
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Figure 7. UVRAG phosphorylation regulates lysosomal tubulation.
A U2OS cells stably expressing LAMP1-mCherry and wild-type (WT) or S550A+S571A (dblA) GFP-UVRAG were transfected with 100 nM control or UVRAG siRNA ~40 h
prior to live cell imaging in complete medium. Representative image are shown from Supplementary Movie S2A–C. Scale bar, 10 lm.
B Quantitation from (A) of mean tubules per cell and tubule length as indicated  SEM for n = 3 independent experiments, significance was determined by one-way
ANOVA and Dunnett's multiple comparison test to the siCTRL, **P < 0.01.
C U2OS cells stably expressing LAMP1-mCherry and WT or dblA GFP-UVRAG were transfected with 100 nM UVRAG siRNA 40 h prior to live cell imaging in complete
medium and treatment with 50 nM lysotracker-648 (LysoTR). Magnified images of tubules from dblA-expressing cells are shown below. Scale bar, 5 lm.
D HeLa cells or those stably expressing WT or dblA GFP-UVRAG were transfected with 100 nM control or UVRAG siRNA ~40 h prior to treatment. Cells were serum-
starved for 2 h before the addition of complete medium and 50 ng/ml EGF before lysis at 0 or 30 min in the presence or absence of 1 lM KU0063794 (KU).
E MEFs stably expressing WT or dblA GFP-UVRAG were transfected with 100 nM control or UVRAG siRNA ~40 h prior to treatment. Cells were incubated in complete
medium (ctrl) or EBSS for 1 h in the presence or absence of 50 nM bafilomycin A1 (Baf).
F Quantitation of normalised LC3-II from (E), mean  SEM for n = 3 independent experiments.
Source data are available online for this figure.
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(Fig 7E and F). Thus, as expected, similar to endosome trafficking,
autophagy induction and autophagosome trafficking to lysosomes
do not require UVRAG phosphorylation.
mTOR-mediated UVRAG phosphorylation enhances cell survival
following long-term starvation
ALR is dramatically induced only after long-term starvation (Yu
et al, 2010); therefore, any defect in lysosome function may only
manifest following longer periods of stress. A prerequisite for the
induction of ALR following starvation is reactivation of mTOR as a
result of increased lysosomal amino acids derived from autophagy
(Yu et al, 2010). To look at mTOR reactivation, we used serum and
glutamine starvation in cells depleted of endogenous UVRAG and
expressing either siRNA-resistant WT or dblA GFP-UVRAG (Fig 8A).
After 2 h of starvation, mTOR activity was reduced in both WT and
dblA-expressing cells, as visualised by loss of phospho-threonine
389 on p70S6K. At around 8 h of starvation, phosphorylation at the
mTOR site of p70S6K started to recover in both WT and dblA cells,
suggesting autophagy was able to deliver enough protein to reacti-
vate mTOR. This is in line with our previous observation suggesting
UVRAG phosphorylation is not required for autophagy. However,
after 10 h of starvation we observed significant cell death only in
dblA UVRAG-expressing cells. To analyse this further, we used time-
lapse microscopy to monitor cell death of UVRAG-expressing cells
(Fig 8B and C). Under the starvation conditions, the majority of cells
died and displayed an apoptotic phenotype with extensive
membrane blebbing followed by leakage of cytosolic contents.
Control-depleted cells and UVRAG-depleted cells expressing WT
GFP-UVRAG were very similar in their rates of cell death that
increased gradually following approximately 20 h of starvation.
What was striking was that cells depleted of endogenous UVRAG
and expressing the dblA mutant showed a much greater sensitivity
to starvation, with a rapid induction of cell death following only 8 h
of treatment. This timing correlates very well with the reactivation of
mTOR in these cells (compare with Fig 8A). As the dblA-expressing
cells have a defect in lysosomal tubulation, it is possible that this acts
as a trigger for cell death under prolonged starvation. Given that
mTOR inhibition prevents tubule formation (Fig 2A and B), we
asked whether this would reverse the increased cell death observed
in the dblA cells. Treatment of WT and dblA cells, which had endo-
genous UVRAG depleted by siRNA, with KU mTOR inhibitor did
indeed increase the survival of the dblA cells under starvation, while
having little effect on the WT GFP-UVRAG-expressing cells (Fig 8D
and E). This suggests the increased tubulation is responsible for the
increased cell death. We do not yet know the mechanism whereby
prolonged tubulation causes cell death, but it is tempting to specu-
late that lysosome integrity is impaired and increased stress leads to
lysosomal membrane permeabilisation and release of hydrolases into
the cytosol. In support of this, we found that dblA-expressing
cells were much more sensitive to lysosomal damage caused by
the lysosomotropic reagent L-leucyl-L-leucine methyl ester (LLOMe,
Maejima et al, 2013). LLOMe treatment for 6 h with our siRNA-
rescue cells resulted in over a twofold increase in cell death in dblA
cells compared to WT UVRAG cells (Fig 8F). We do note however
that the cell death mechanism may be independent of lysosomal
tubules, especially given that UVRAG has been implicated in
DNA repair (Zhao et al, 2012). However, based on this study, we
found no difference in WT vs. dblA UVRAG interaction with the
Ku70–DNA–PK complex (Supplementary Fig S6A). Neither did we
see any increase in DNA damage in WT vs. dblA-expressing cells, as
indicated by c-H2AX staining under normal or starvation conditions
as well as UV-induced DNA damage (Supplementary Fig S6B and C).
Taken together, the data currently suggest that persistent lysosomal
tubulation, caused by loss of mTOR-mediated UVRAG phosphoryla-
tion, severely impedes cell survival and that the regeneration of lyso-
somes following starvation is critical to this process.
Discussion
The data presented here uncover a direct role for VPS34 lipid kinase
activity in regulating lysosomal or, more specifically autolysosomal,
tubulation. Two strong lines of evidence led to this conclusion.
Firstly, pharmacological inhibition of VPS34 using limiting concen-
trations of VPS34-IN1, which was sufficient to deplete an identified
lysosomal pool of PI(3)P, resulted in a significant increase in lyso-
somal tubules. Secondly, loss of newly discovered mTOR phosphor-
ylation sites on UVRAG that caused a reduction in VPS34 activity
also led to a large increase in lysosomal tubules. The observation
that trafficking prior to the lysosome appeared unaffected by the
loss of UVRAG phosphorylation implies that the lysosome itself is
the major site for this form of regulation. Indeed, this is where
active mTOR is localised (Sancak et al, 2010; Betz & Hall, 2013),
and as we now show here, UVRAG too.
mTOR and VPS34 have a complex relationship, and multiple
studies have shown that nutrient starvation, and inhibition of
mTOR, reduce total cellular PI(3)P levels (Byfield et al, 2005;
Russell et al, 2013; Yuan et al, 2013). However, this is not so simple
as it first seems as there is more than one cellular pool of PI(3)P,
such as that present at early endosomes, autophagosomes or as
identified here, lysosomes. These pools can be differentially regu-
lated, in part due to the different complexes of VPS34. This is most
striking upon inhibition of mTOR and autophagy induction, where
the autophagic pool of PI(3)P is dramatically increased, in part
through phosphorylation/dephosphorylation of the VPS34–
BECLIN1–ATG14L complex by AMPK (Kim et al, 2013), ULK1
(Russell et al, 2013) and mTOR (Yuan et al, 2013) kinases. This is
in contrast to the endocytic and newly identified lysosomal pools
that are decreased, which we now show is due to dephosphorylation
of the distinct VPS34–BECLIN1–UVRAG complex. Taken together,
this suggests that VPS34 and its associated complexes act as signal-
ling nodes to drive and co-ordinate multiple trafficking pathways.
We do note that during the submission of this manuscript, a paper
was published describing mTOR phosphorylation of UVRAG at
serine 498 (S498) (Kim et al, 2015) However, phosphorylation
inhibited VPS34 activity through enhanced RUBICON binding and
decreased trafficking of endosomes and autophagosomes to the
lysosome. This is somewhat at odds with the data presented here.
We did identify S498 of UVRAG as being phosphorylated in cells;
however, unlike S550 and S571, this was not affected by mTOR inhi-
bition and mutation of this site did not reduce endogenous mTORC1
phosphorylation of UVRAG in vitro (Supplementary Fig S3). Simi-
larly, mTOR inhibition by treatment with KU or EBSS did not alter
the binding of RUBICON to the VPS34 complex (Fig 5G). We also
found that mTOR inhibition reduced VPS34 activity, which is
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Figure 8. Loss of UVRAG phosphorylation impairs survival under conditions of ALR.
U2OS cells stably expressing wild-type (WT) or S550A+S571A (dblA) GFP-UVRAG were transfected with 100 nM UVRAG siRNA 40 h prior to treatment.
A Cells were serum-starved in DMEM without glutamine for up to 10 h and lysed at time points indicated.
B Cells were grown in glutamine-free DMEM and monitored by bright-field microscopy with images captured every 10 min up to 42 h. Scale bar, 10 lm.
C Quantitation of (B) represents mean % live cells relative to time  SEM for n = 3 independent experiments.
D Cells were grown in serum and glutamine-free DMEM for 12 h prior to the addition of DMSO or 1 lM KU and monitored by bright-field microscopy. Scale bar,
10 lm.
E Quantitation of (D) represents mean % live cells relative to time  SEM for n = 3 independent experiments.
F Cells were grown in complete medium in the presence or absence of 1 mM LLOMe and monitored by bright-field microscopy. Scale bar, 10 lm.
G Quantitation of (F) represents mean % live cells relative to time  SEM for n = 3 independent experiments. Significance was determined by two-way ANOVA and
Bonferroni post-test, *P < 0.05 and ***P < 0.001.
Source data are available online for this figure.
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consistent with the previously published work from other groups
(Byfield et al, 2005; Russell et al, 2013; Yuan et al, 2013). We
cannot fully explain these discrepancies, but an obvious explanation
is that in our cellular systems at least, another kinase is responsible
for UVRAG phosphorylation at S498.
The autolysosomal tubulation observed here differs somewhat for
the original observations of ALR (Yu et al, 2010). Firstly, we find
tubulation occurs under normal nutrient-rich growth conditions. We
take this to mean that ALR is constantly occurring, but under these
basal conditions, it is not as evident as those following longer-term
starvation. The fact that we are blocking this process by VPS34 inhibi-
tion allows us to more easily visualise it here. Secondly, the classical
ALR tubules are not positive for lysotracker or cargo such as LC3,
whereas the tubules described here are positive for both. A potential
explanation for this may partially due to the persistent nature of the
tubules: their prolonged existence may mean it is more likely that the
quality control mechanisms to prevent passage of cargo into tubules
are overcome. Further work will be needed to clarify this situation.
mTOR activity has previously been shown to regulate lysosomal
tubulation, being essential for the process of ALR, through an
unknown mechanism. Our study now provides a further link in
showing that mTOR is needed not only for tubule initiation, but also
for tubule maintenance by phosphorylating UVRAG and activating
VPS34. We do not yet know the exact function of PI(3)P in regulat-
ing lysosomal tubules, though given the persistent and extended
phenotype upon VPS34 inhibition, it is tempting to suggest a role in
tubule scission from the donor lysosome. Dynamin 2 has been
shown to play an important role in tubule scission at lysosomes,
and the use of the dynamin inhibitor dynasore rapidly induces a
similar LAMP1-positive tubular phenotype (Schulze et al, 2013).
Dynamin activity has been shown to be activated by multiple phos-
phoinositides, including PI(3)P, PI(4)P and PI(4,5)P2, in vitro (Yarar
et al, 2008). Interestingly, this same study showed that the PX
domain containing protein SNX9 synergised with PI(3)P and other
phosphoinositides to stimulate dynamin activity further. We are
currently investigating whether these proteins are involved in the
tubulation observed here.
Another candidate PI(3)P-binding protein that may regulate
lysosomal tubulation is SPASTIZIN/SPG15/FYVE-CENT, the gene of
which is frequently mutated hereditary spastic paraplegia (HSP)
(Hanein et al, 2008). Work on zebrafish oocytes showed that
SPASTIZIN is required for vesicle scission from lysosome-related
cortical granules, potentially by regulating dynamin (Kanagaraj
et al, 2014). Very recently in human cells, SPASTIZIN was shown to
be important for ALR (Chang et al, 2014). This study showed that
the FYVE domain of SPASTIZIN is important for its lysosomal locali-
sation, which strongly supports our data showing PI(3)P at the lyso-
some. The study also found that loss of SPASTIZIN impaired
lysosomal tubulation, which is in contrast to our study that showed
persistent tubules upon VPS34 inhibition. However, it was not clear
from this study whether the block in tubulation is due to the PI(3)P-
binding properties of the protein. It is also interesting to note that
lysosomes were still functional upon loss of SPASTIZIN, in agree-
ment with our results in cells expressing the dblA UVRAG mutant.
Phosphoinositides play an important role in lysosomal tubula-
tion, and not just through the potential interaction with dynamin as
mentioned above. Two important studies showed that PI(4)P and
PI(4,5)P2 play essential roles in controlling tubule initiation. The
first study showed that PI(4,5)P2, produced by PIP5K1B at lyso-
somal budding sites, led to the recruitment of the clathrin machin-
ery to enable tubule formation (Rong et al, 2012). The same study
also showed that the related kinase, PIP5K1A, localised to the lead-
ing edges of tubules and the produced PI(4,5)P2 aided in tubule
scission. The second study showed that PI4KIIIb, a lipid kinase
responsible for PI(4)P production, is also required to allow
controlled tubule production (Sridhar et al, 2013). This is not only
by providing PI(4)P, the substrate for the PIP5Ks to make PI(4,5)P2,
but also to prevent uncontrolled tubulation that occurred upon loss
of PI4KIIIb. The enhanced formation of lysosomal tubules upon loss
of PI4KIIIb is somewhat similar to the tubules formed upon loss of
VPS34 activity described here, implying that lysosomal PI(3)P could
be involved in preventing tubule formation rather than controlling
scission from lysosomes. However, the tubules formed upon loss of
VPS34 activity differ somewhat from those produced by loss of
PI4KIIIb. The VPS34-dependent tubules stain with lysotracker (see
Fig 6C), while the PI4KIIIb-dependent tubules do not. In fixed cells,
loss of VPS34 activity through the UVRAG phospho-mutant results
in an increased number of small, evenly distributed LAMP1 puncta
A
B
Figure 9. Model of PI(3)P-mediated lysosomal regulation.
A Autophagic lysosomal regulation (ALR) and tubulation is driven by the
conversion of PI(4)P to PI(4,5)P2 but is fundamentally dependent upon
mTOR activity for initiation via unknown mechanisms.
B mTOR acts at a secondary step via phosphorylation of UVRAG to increase
formation of lysosomal PI(3)P that appears to be critical for tubule scission,
a process regulated by the GTPase dynamin.
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(see Fig 5A), while loss of PI4KIIIb shows a clustered pattern of
large LAMP1 structures.
Having three different forms of phosphoinositide may seem an
excessive requirement for controlling lysosomal tubulation.
However, having such a requirement for different modifications of a
single inositide lipid allows for rapid control of signalling and matu-
ration of the tubulation process. Interestingly, PI(3)P and PI(4,5)P2
have been shown to co-operate to drive actin assembly and it is
possible this kind of regulation could be happening during lyso-
somal tubulation (Gallop et al, 2013). A simple model for the roles
of these lipids is summarised in Fig 9. Clearly, more work is needed
to fully characterise and understand the relationships between these
three different phosphoinositides and the mechanisms that coordi-
nate their kinases and phosphatases. Regardless, the process of
tubulation appears to be essential for normal cell function. Though
ALR has been characterised, it has been difficult to show the specific
consequences that disrupting the process has on cell survival. The
identification of a phospho-mutant of UVRAG that alters lysosomal
tubulation, yet does not significantly affect endocytic trafficking,
has allowed us to look into this in more detail. The increased rate
of cell death upon starvation in the dblA UVRAG cells does indeed
suggest ALR tubulation is essential in maintaining lysosomal func-
tion and cell survival, especially as this can be reversed by mTOR
inhibition. Given the recent SPASTIZIN link to ALR (Chang et al,
2014), the results presented here suggest increased rates of cell
death could be responsible for the degeneration of motorneurons
in HSP. Though the mechanisms of cell death appear to have the
hallmarks of apoptosis, we do not yet know how it is triggered;
though with the increased susceptibility of the dblA UVRAG
mutant cells to lysosomal damage, it is tempting to speculate that
lysosomal integrity is impaired leading to the release of hydrolases
into the cytosol.
The work presented here not only shows that the nutrient-
sensing mTOR protein kinase directly activates the membrane
trafficking VPS34 lipid kinase, but that this activation is important
in regulating lysosomal tubulation and survival during starvation.
Given the link between lysosomes and cell survival with many
diseases such as neurodegeneration and cancer, further analysis of
this pathway may lead to future therapeutic approaches.
Materials and Methods
Materials
Antibodies (with catalogue number) against 4E-BP1 (9452), DNA-
PKc (4602), EEA1 (2411), GM130 (2296), c-H2AX (2577), mTOR
(2983), p70S6K (2708), p70S6K P-T389 (9205), RUBICON (8465),
a-tubulin (2125) and ULK1 P-S757 (6888) were from Cell Signaling
Technologies. GST-HRP (Ab3461) and CI-MPR (ab2733) were from
Abcam. GFP (11814460001) was from Roche. FLAG-HRP (A8592),
LAMTOR1 (HPA002997) and ULK1 (A7481) were from Sigma-
Aldrich. EGFR (sc-03), CD63 (sc-5275) and LAMP1 (sc-20011) were
from Santa Cruz Biotechnology, Inc. ATG14L (PD026) and Beclin1
(PD017) were from MBL International Corporation. Sheep anti-
UVRAG was generated against full-length human GST-UVRAG and
affinity-purified by the Division of Signal Transduction Therapy
(DSTT), University of Dundee. Phospho-specific antibodies
against UVRAG S550 and S571 were also generated in sheep and
affinity-purified by the DSTT. The following peptides were used for
immunisation: S550—KITSLSSS*LDTSLD and S571—KKGEDLVGS*
LNGGHANRR.
All cDNA constructs and antibodies against LC3, RAPTOR,
RICTOR, UVRAG, UVRAG P-S550, UVRAG P-S571 and VPS34 were
generated by the DSTT. All recombinant proteins, plasmids and
antibodies generated for the present study are available upon
request and are described in further detail on our reagents website
(https://mrcppureagents.dundee.ac.uk/).
Alexa Fluor-594 labelling kit (A30008), ProLong gold antifade
mountant with DAPI (P36931), lysotracker-648 (L12492) and trans-
ferrin-594 (T-13343) were from Life Technologies. Bafilomycin A1
was purchased from Enzo and KU0063794 from Tocris. Leu-leu
methyl ester hydrobromide (LLOMe) was purchased from Sigma.
Cell culture and lysis
U2OS, HeLa, mouse embryonic fibroblasts (MEFs) and HEK293
cells were maintained in a complete medium of DMEM (Gibco)
supplemented with 10% foetal bovine serum (FBS, Hyclone), 2 mM
L-glutamine (Lonza) and 1% penicillin and streptomycin (Lonza).
Cells were cultured within a humidified environment at 37°C with
5% CO2. Wild-type and knockout RICTOR MEFs (Shiota et al, 2006)
were provided by Prof. M. Magnuson (Vanderbilt University School
of Medicine, USA).
For lysis, cells were washed twice on ice with PBS and subse-
quently scraped with ice-cold NP-40 lysis buffer (50 mM Hepes
pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 0.5% NP-
40) unless otherwise stated. All lysis buffers were supplemented
with 1 mM DTT, 1 mM PMSF and phosphatase inhibitors. Samples
were clarified by centrifugation at 20,000 g for 10 min at 4°C and
protein concentration determined by Bradford (500-0006, Bio-Rad
protein assay).
Transfections
Stable cell lines were generated by retroviral transduction. The
pBabe construct of interest was co-transfected into 293FT cells
with GAG/POL and VSV-G expression plasmids (Clontech) for
retrovirus production using Lipofectamine 2000 (Life Technologies)
as per the manufacturer’s instructions. Virus was harvested 48 h
post-transfection, passed through a 0.45-lm filter and added to
target cells in the presence of 10 lg/ml polybrene (Sigma). After
24 h, cells were selected by addition of 10 lg/ml puromycin
(Sigma) and utilised for experiments following complete death of
non-transfected controls.
For knockdown of endogenous UVRAG, cells were transiently
transfected with a previously described siRNA—GGACAAAGGAAG
TGCATTT (Liang et al, 2006). siRNA was transfected using Trans-
fectin (Bio-Rad) as per the manufacturer’s protocol, and cells were
typically utilised for experiments ~40 h post-transfection.
PI(3)P PX domain staining
For selective PI(3)P staining, the GST-tagged PX domain (residues
1–148 of p40phox) was expressed in E. coli (BL21) and purified over
a glutathione column using standard procedures. The recombinant
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protein was chemically conjugated to Alexa Fluor-594 as per the
manufacturer’s protocol.
For staining, following treatment cells were washed once on ice
with phosphate-buffered saline (PBS) and glutamate buffer (25 mM
Hepes pH 7.4, 25 mM KCl, 2.5 mM Mg-acetate, 5 mM EGTA,
150 mM K-glutamate). Coverslips were snap-frozen in liquid N2 and
thawed prior to two further washes with ice-cold glutamate buffer.
Cells were fixed with 3.7% (w/v) formaldehyde, 200 mM Hepes
pH 7.4 for 30 min at RT and subsequently quenched by two washes
and incubation for 10 min in 10 mM Hepes pH 7.4, DMEM. Samples
were blocked by washing twice and incubated for 30 min in block-
ing buffer (1% (w/v) BSA, PBS). Coverslips were incubated for 1 h
at RT with 5 lg/ml PX domain conjugate and washed three times in
blocking buffer. Coverslips were washed once more in ddH2O prior
to mounting with ProLong Gold antifade mountant.
Electron microscopy
Immuno-EM was carried out on cells fixed in 1% glutaraldehyde in
0.2 M PIPES buffer pH 7.2. After pelleting and cryoprotection in
2.1 M sucrose in PBS, ultra-thin frozen sections were cut at 100°C
(EM FC7 ultracryomicrotome; Leica, Vienna, Austria). Labelling for
LAMP1 was performed at room temperature followed by secondary
rabbit anti-mouse (Southern Biotech). Labelling for PI(3)P was at
low temperature (Watt et al, 2002) using the GST-PX domain
followed by antibodies against GST (Abcam, cat no 9085). Molecu-
lar contrasting was completed using 10 nm protein A gold from BBI,
and structure contrasting was achieved using uranyl acetate-methyl
cellulose (according to Griffiths et al, 1984). After air-drying, the
sections were imaged using a JEOL 1200- transmission electron
microscope at 80 kV and images taken with a Gatan Orius 200 digi-
tal camera (Gatan, Abingdon Oxon).
Live cell imaging
For live cell imaging experiments, cells were seeded onto glass-
bottom dishes (627870, Greiner Bio One) a minimum of 16 h prior
imaging. Treatments were carried out in phenol red-free DMEM
buffered with 20 mM Hepes pH 7.4, and imaging was carried out by
widefield deconvolution microscopy (Deltavision Elite, GE Health-
care) in a heated environment chamber. Images were acquired and
deconvolved using softWoRx 5.0 (Applied Precision, GE Healthcare).
For long-term starvation treatments, cells were maintained in a
humidified environmental chamber with 5% CO2 and imaged by
bright-field (Eclipse TiE, Nikon Instruments). Images were acquired
and analysed utilising NIS-Elements (Nikon Instruments).
mTORC1 in vitro kinase assay
HEK293 cells were grown in complete medium and stimulated with
50 ng/ml IGF1 for 30 min to hyper-activate mTOR prior to lysis in
CHAPS buffer (20 mM Tris pH 7.4, 137 mM NaCl, 2 mM EDTA,
10% (v/v) glycerol, 2% (w/v) CHAPS). Endogenous RAPTOR was
immunoprecipitated with Protein G Sepharose and washed twice
with CHAPS buffer + NaCl (0.5 M total), twice with CHAPS buffer
and twice with kinase buffer (25 mM Hepes pH 7.4, 50 mM KCl)
and left with ~10 ll buffer on the beads. Per reaction, 1 lg
substrate was added in 20 ll kinase buffer prior to the addition of
10 ll ATP mix (40 mM MnCl2, 80 lM ATP, 1 lCi
32P c-ATP in
kinase buffer). Reactions were agitated at 30°C for 30 min and
terminated by addition of 10 ll 5× sample buffer (300 mM
Tris pH 6.8, 8% (w/v) SDS, 50% (v/v) glycerol, 0.025% (w/v)
bromophenol blue).
Samples were separated by SDS–PAGE and transferred to PVDF
membrane before detection of 32P incorporation by autoradio-
graphy.
Mass spectrometry
Samples were resolved by SDS–PAGE and Coomassie staining
(ISB1L, Expedeon), and bands were excised and processed for mass
spectrometry. Samples were alkylated in gel with iodoacetamide
(Sigma) and digested overnight with trypsin gold (V5280, Promega).
Peptides were extracted and analysed by LC-MS/MS using an Orbi-
trap Classic mass spectrometer (Thermo Scientific). Proteins and
phosphorylation sites were identified from peptides by Mascot soft-
ware (Matrixscience). Phosphorylation sites were represented by
comparison of the extracted ion chromatograms between samples in
Xcalibur (Thermo).
VPS34 in vitro kinase assay
Cells were treated as described in figure legends prior to lysis in
NP-40 lysis buffer. Endogenous or exogenous UVRAG was immuno-
precipitated, and beads were washed twice in NP-40 lysis buffer
+ 0.5 M NaCl (final), twice with NP-40 lysis buffer and finally twice
with lipid kinase assay (LKA) buffer (10 mM MnCl2, 20 mM Tris
pH 7.5, 67 mM NaCl, 0.02% (w/v) CHAPS).
Associated VPS34 was assayed in vitro with a final concentration
of 10 lg phosphatidylinositol (PI) liposomes (bovine liver PI,
extruded through a 100-nm filter—Avanti Mini-Extruder), 5 lM
ATP and 7.5 lCi 32P c-ATP in LKA buffer. Reactions were agitated
for 30 min at 30°C before centrifugation through a Spin-X column to
isolate beads, and the addition of 500 ll methanol:chloroform:
hydrocholoric acid (200:100:3.5) terminated the reaction. 1× sample
buffer (50 mM Tris pH 6.8, 2% (w/v) SDS, 10% glycerol (v/v),
0.005% bromophenol blue) was added to the beads removed by
Spin-X and analysed by Western blot as a control for VPS34 levels.
A total of 180 ll of chloroform and 300 ll of 0.1 M hydrochloric
acid were added to the solvent of each sample and centrifuged at
1,000 g for 1 min at RT to phase-split components. The lower lipid-
containing chloroform layer was retained and dried by centrifugal
evaporation. Lipids were re-dissolved in chloroform and spotted
onto thin layer chromatography (Silica 60, Merck-Millipore) acti-
vated in potassium oxalate (1% (w/v) potassium oxalate, 5 mM
EDTA, 50% (v/v) methanol). Plates were ran in a solvent system
comprised of methanol:chloroform:water:ammonium hydroxide
(47:60:11.2:2) to separate phosphoinositol products. Once dried, the
incorporation of 32P was quantified by phosphorimager (FLA-2000,
Fujifilm) and AIDA image analyser (Raytest). Values were norma-
lised to VPS34 level determined by Western blot.
Laser microirradiation
Cells were grown on glass-bottom dishes in complete medium and
in the presence of 10 lM BrdU for 48 h. Laser micro-irradiation was
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carried across the nuclei in 100 cells per condition with a 405-nm
laser attached to a PALM microscope (Zeiss). Cells were then
returned to 37°C for 1 h prior to fixation with 3.7% (w/v) formalde-
hyde, 200 mM Hepes pH 7.4 and then immunofluorescence staining
for GFP and c-H2AX to visualise laser-induced damage.
Quantitation
Western blots and mTOR kinase assays were quantified by densi-
tometry using ImageJ. Immunofluorescence images were quantified
for cell intensity, punctate structures and co-localisation utilising
NIS-Elements. Automated counting was carried out by intensity
thresholding, and the criteria set was kept consistent within experi-
ments between conditions and checked thoroughly to ensure accu-
rate representation of the data. Typically, 5–10 fields of view were
analysed per condition (50+ cells minimum) per experimental repli-
cate. LAMP1 tubule length and number were analysed by ImageJ.
For tubule analysis, typically 5–10 cells per condition were quanti-
fied per experimental replicate.
Statistics
Statistical analysis and post hoc tests were carried out as described
in figure legends using GraphPad Prism v5.0. The statistical signifi-
cance is denoted on graphs by asterisks (*), where *P < 0.05,
**P < 0.01, ***P < 0.001 and n.s = not significant.
Supplementary information for this article is available online:
http://emboj.embopress.org
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